Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.
Purpose: Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 46; no. 3; pp. 728 - 743 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |